Inmunoterapia en 1L del CPCNP: monoterapia y/o tratamiento combinado - page 30

Gettinger S, et al. WCLC 2016
Nivo 3 Q2W
(n = 52)
Nivo 3 Q2W
+ Ipi 1 Q12W
(n = 38)
Nivo 3 Q2W
+ Ipi 1 Q6W
(n = 39)
Any grade Grade 3–4 Any grade Grade 3–4 Any grade Grade 3–4
Treatment-related AEs, % 73 19 84 42 74 31
Treatment-related AEs leading to
discontinuation, % 12 12 18 8 18 8
Nivolumab plus Ipilimumab